Reasons for buying:
Market Cap: ₹28,306 Cr (Bluechip stock)
Debt to Equity: 0.16
Return on Equity 5Y Avg: 22.26%
EPS - 5Y Growth: 30.27%
Price-earnings to growth (5Y): less than 1.5
5Y RoE Consistency - Sustained without losing 20% in any year
***
Buy date: 9-Sep-2022
Qty: 11 Buy Price: ₹854.85 Buy EPS: 36.73
New Price after demerger: ₹646.10
***
Buy date: 29-Sep-2022
Qty: 13 Buy Price: ₹769 Buy EPS: 36.73
New Price after demerger: ₹581.21
Will continue to add when a stock falls 10% as long as the ratios remain the same. The stock would take a long time to pay, it lost 10% in 20 days.
***
Buy date: 20-Oct-2022
Qty: 14 Price: ₹683 EPS: 36.73
***
Due to the demerger, the cost of the acquisition of my shares changed.
Sr. No. Name of the Company Percentage of cost of acquisition of equity shares
1 Aarti Pharmalabs Limited (Resulting Comoanvl 24.42%
2 Aarti Industries Limited (Dernerged Cornoanvl 75.58%
Total 100.00%
Aarti Industries manufactures and sells chemicals and chemical-based products in two segments based on the product type. The specialty chemical segment which generates the majority of revenue sells benzene-based chemicals which are used in agricultural products dyes and pigments and flavors and fragrances. The pharmaceuticals segment sells drugs used to treat diarrhea, inflammation, and asthma as well as antibiotics and antidiabetics. More revenue comes from India than any other country or region.
No comments:
Post a Comment